In This Section      
Print This Page

Search Results

Rare and Cutaneous Non-Hodgkin Lymphoma Registry
Protocol Number:
Kenneth Cohen
Johns Hopkins Kimmel Cancer Center in Baltimore
The goals of this study is -to learn more about lymphoma, how it presents, and whether it behaves differently from the same lymphoma in adults. -To find out what treatment is being used for these rare diseases. -to register all subjects under age 21 years who present with an uncommon type of lymphoma or a lymphoma at an uncommon site such as the brain or skin.
-Any NHL histology, except Burkitt/Burkitt-like, diffuse large B-cell, anaplastic large cell and lymphoblastic lymphomas. All primary CNS and cutaneous lymphomas of any histology are eligible as are all lymphoproliferative diseases. -Pathology from site not treated in past 6 months. -Age 0-20.99 years. -All primary cutaneous NHL â?? any histology. -All primary CNS NHL â?? any histology. -Materials must be available for Pathology Central Review.
You are going to have a biopsy (or surgery) to see if you have cancer. Your study doctor will remove some tissue to make the diagnosis of your disease. The results of these tests will be given to you by your study doctor and will be used to plan your care. We would like to keep some of the tissue that is left over for future research. If you agree, this tissue will be kept and may be used in research to learn more about cancer and other diseases. Drawing samples of blood and getting samples of bone marrow are often part of standard of care for subjects who may have cancer. When blood is taken for standard tests, subjects will be asked to give an extra 3 teaspoons of blood for special research studies. If you are not having standard blood work done, you will be asked to provide 3 teaspoons of blood. If a bone marrow sample is being taken for clinical purposes, you will be asked to provide an extra 1-2 teaspoons of bone marrow. No additional bone marrow tests or other invasive tests will be asked of you. Characteristics in the samples of blood may be compared with those in the tumor. Some of the tissue used to make the diagnosis of your disease will be sent to central review centers. This is to confirm that you are eligible to have samples banked on this study. The results will not be given to you or your doctor.
Last Update
12/10/2017 05:03 AM